KEYNOTE-966 HRQoL
KEYNOTE-966: Health-Related Quality-of-Life Outcomes With Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Advanced Biliary Tract Cancer

Released: June 06, 2023

Activity

Progress
1
Course Completed